Phase I dose finding studies of an adjuvanted Clostridium difficile toxoid vaccine

Vaccine

Volumn 30, Issue 13, 2012, Pages 2245-2249

  Greenberg, Richard N ^a   Marbury, Thomas C ^b   Foglia, Ginamarie ^c   Warny, Michel ^c  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^b ORLANDO CLINICAL RESEARCH CENTER   (United States)

^c SANOFI PASTEUR   (France)

Author keywords

Clostridium difficile; Dose finding; Immunogenicity; Safety; Vaccine

Indexed keywords

CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; CLOSTRIDIUM DIFFICILE TOXOID; IMMUNOGLOBULIN G; PLACEBO; TOXOID; UNCLASSIFIED DRUG;

ADULT; AGED; ANOREXIA; ARTICLE; BACKACHE; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; EOSINOPHIL COUNT; FATIGUE; FEMALE; GROUPS BY AGE; HEADACHE; HUMAN; HUMAN EXPERIMENT; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE IRRITATION; INJECTION SITE PAIN; INJECTION SITE PARESTHESIA; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; INJECTION SITE WARMTH; LEUKOCYTE COUNT; MALE; MYALGIA; NORMAL HUMAN; PAIN; PHASE 1 CLINICAL TRIAL; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSATION OF HEAVINESS; SENSORY DYSFUNCTION; SEROCONVERSION; SEROLOGY; SIDE EFFECT; TREATMENT WITHDRAWAL;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BACTERIAL VACCINES; CLOSTRIDIUM DIFFICILE; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DOUBLE-BLIND METHOD; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; HUMANS; MALE; MIDDLE AGED; TOXOIDS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84857793535     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.01.065     Document Type: Article

References (14)

1. Kyne L., Farrell R.J., Kelly C.P. Clostridium difficile. Gastroenterol Clin North Am 2001, 30(3):753-777. ix-x.
2. Vaishnavi C. Clinical spectrum and pathogenesis of Clostridium difficile associated diseases. Indian J Med Res 2010, 131:487-499.
3. Dupont H.L., Garey K.W. Clostridium difficile infection: an emerging epidemic with more questions than answers. Future Microbiol 2010, 5(8):1153-1156.
4. Asensio A., Vaque-Rafart J., Calbo-Torrecillas F., Gestal-Otero J.J., López-Fernández F., Trilla-Garcia A., et al. Increasing rates in Clostridium difficile infection (CDI) among hospitalised patients, Spain 1999-2007. Euro Surveill 2008, 13(31). pii: 18943.
5. Pépin J., Valiquette L., Alary M.E., Villemure P., Pelletier A., Forget K., et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004, 171(5):466-472.
6. Elixhauser A, Jhung MA. Clostridium difficile-associated disease in U.S. hospitals, 1993-2005; HCUP statistical brief #50 2008. Accessed 5 October 2011 at: http://www.hcup-us.ahrq.gov/reports/statbriefs/sb50.jsp.
7. Kyne L., Warny M., Qamar A., Kelly C.P. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001, 357(9251):189-193.
8. Kyne L., Warny M., Qamar A., Kelly C.P. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000, 342(6):390-397.
9. Leav B.A., Blair B., Leney M., Knauber M., Reilly C., Lowy I., et al. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine 2010, 28(4):965-969.
10. Kotloff K.L., Wasserman S.S., Losonsky G.A., Thomas W., Nichols R., Edelman R., et al. Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults. Infect Immun 2001, 69(2):988-995.
11. Aboudola S., Kotloff K.L., Kyne L., Warny M., Kelly E.C., Sougioultzis S., et al. Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A. Infect Immun 2003, 71(3):1608-1610.
12. Sougioultzis S., Kyne L., Drudy D., Keates S., Maroo S., Pothoulakis C., et al. Clostridium difficile toxoid vaccine in recurrent C difficile-associated diarrhea. Gastroenterology 2005, 128(3):764-770.
13. Evans D.G. Persistence of antitoxin in man following active immunisation. Lancet 1943, 2:316-317.
14. Plotkin S.L., Plotkin S.A. A short history of vaccination. Vaccines 2005, 1-36. Saunders Co., PA, USA. 5th edition. S.L. Plotkin, W. Orenstein, P.A. Offit (Eds.).